Critical Survey: Corpay (NYSE:CPAY) vs. OptimizeRx (NASDAQ:OPRX)

Corpay (NYSE:CPAY) and OptimizeRx (NASDAQ:OPRX) are both business services companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Corpay and OptimizeRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corpay	0	3	11	1	2.87
OptimizeRx	0	3	6	0	2.67

Corpay currently has a consensus target price of $381.43, indicating a potential upside of 0.49%. OptimizeRx has a consensus target price of $9.06, indicating a potential upside of 56.52%. Given OptimizeRx’s higher probable upside, analysts clearly believe OptimizeRx is more favorable than Corpay.

Institutional & Insider Ownership

98.8% of Corpay shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 6.1% of Corpay shares are owned by company insiders. Comparatively, 6.1% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Corpay and OptimizeRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corpay	$3.76 billion	7.04	$981.89 million	$14.02	27.07
OptimizeRx	$71.52 million	1.49	-$17.57 million	($1.33)	-4.35

Corpay has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Corpay, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Corpay has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares Corpay and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corpay	26.14%	39.44%	7.54%
OptimizeRx	-27.41%	-4.92%	-3.41%

Summary

Corpay beats OptimizeRx on 12 of the 14 factors compared between the two stocks.

About Corpay

Corpay, Inc. operates as a payments company that helps businesses and consumers manage vehicle-related expenses, lodging expenses, and corporate payments in the United States, Brazil, the United Kingdom, and internationally. The company offers vehicle payment solutions, which include fuel, tolls, parking, fleet maintenance, and long-haul transportation services, as well as prepaid food and transportation vouchers and cards. It also provides corporate payment solutions consisting of accounts payable automation; virtual cards, cross-border solutions; and purchasing and travel and entertainment card products, as well as lodging payments solutions for employees who travel overnight for work purposes; traveling crews and stranded passengers from airlines and cruise lines; and insurance policyholders displaced from their homes due to damage or catastrophe. In addition, the company offers gifts and payroll cards. It serves business, merchant, consumer, and payment network customers. The company was formerly known as FLEETCOR Technologies, Inc. and changed its name to Corpay, Inc. in March 2024. Corpay, Inc. was founded in 1986 and is headquartered in Atlanta, Georgia.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.